Back to search

Peptide record

TPDB22019

MAP MAP-anti-gyrA PNA/scPNA C2 PTD4 Antibacterial Antiviral Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB22019
MAP MAP-anti-gyrA PNA/scPNA C2 PTD4
Antibacterial Antiviral Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
Peptipedia AVPpred-BWR BBPpredict CellPPD CellPPD-MOD CPPsite3.0 HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Antiviral, Blood-Brain Barrier, and other sources) peptide sequence curated from Peptipedia, AVPpred-BWR, BBPpredict, and other sources, with an available 3D structural model.
Sequence
KLALKLALKALKAALKLA
Physicochemical Analysis
C90H169N23O19
RNDCEQGHIMFPSTWYV
L
1877.47
11.12
5
0
13
+5
0.01
0.994
185.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
6
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
7
L
5
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 6 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 7 K: 5 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
18
C90H169N23O19
1877.47
11.12
+5
0.01
0.994
Free
L
Amphipathic
Linear
Free
N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C(C)C)C(=O)O N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)O N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C)C(=O)O
Evidence Records 12 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

C166-eGFP cells

Source & Reference

CPPsite3.0
CPPsite3
WO 2011/020188 A1

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Synthetic
Nucleic acid (siRNA)
In vitro
CCTTTCTHHHHHHHTTCC
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

S. Aureus Infected Mac-T Or Hbmec Cell Lines , Ex Vivo Calvaria (Skull Cap)

Assay & Model

Femur injury model (Wistar rats (5 to 6 wks of age))
Femur injury model (Wistar rats (5 to 6 wks of age))

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Synthetic
Lysostaphin and LysK
In vitro and in vivo
CCSSTHHHHSSCCSSSCSCCCC
Evidence 3 Activity

Activity

Cell-penetrating Peptides

Target

S. Pyogenes Strains

Assay & Model

G. mellonella Larvae
G. mellonella Larvae

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
anti-gyrA antisense PNAs and scrambled PNAs [scPNAs]
In vitro and in vivo
CCHHHHTTCC
Evidence 4 Activity

Activity

Cell-penetrating Peptides

Target

Wheat Microspores

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Synthetic
Cys-mCherry protein
Lowest interaction with the microspore cell wall
In vitro
CTTTSCCCCHHHHHTGGGGTC
Evidence 5 Activity

Activity

Cell-penetrating Peptides

Target

LO2 (Human liver cell)

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
In vitro
CCCCSCC
Evidence 6 Activity

Activity

25% Hemolysis
Toxicity
13.1 µM
Hemolytic Cytotoxic
25% Hemolysis | 13.1 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Immobilization reduces the activity of surface-bound cationic antimicrobial peptides with no influence upon the activity spectrum. | Antimicrob Agents Chemother | 2009
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
50% Hemolysis | 10 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. | Biochemistry | 1996
Evidence 8 Activity

Activity

100% Hemolysis
Toxicity
32-1024 µg/mL
Hemolytic Cytotoxic
100% Hemolysis | 32-1024 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influence of C-terminal amidation on the antimicrobial and hemolytic activities of cationic a-helical peptides | Pure Appl Chem | 2007
Evidence 9 Activity

Activity

25% Hemolysis
Toxicity
9.1 µM
Hemolytic Cytotoxic
25% Hemolysis | 9.1 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Immobilization reduces the activity of surface-bound cationic antimicrobial peptides with no influence upon the activity spectrum. | Antimicrob Agents Chemother | 2009
Evidence 10 Activity

Activity

86% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
86% Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influence of C-terminal amidation on the antimicrobial and hemolytic activities of cationic a-helical peptides | Pure Appl Chem | 2007
Evidence 11 Activity

Activity

100% Hemolysis
Toxicity
64-1024 µg/mL
Hemolytic Cytotoxic
100% Hemolysis | 64-1024 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influence of C-terminal amidation on the antimicrobial and hemolytic activities of cationic a-helical peptides | Pure Appl Chem | 2007
Evidence 12 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis
Additional Detail Fields 1 fields
CCTTTCTHHHHHHHTTCC CCSSTHHHHSSCCSSSCSCCCC CCHHHHTTCC CTTTSCCCCHHHHHTGGGGTC CCCCSCC